Cytek Biosciences (CTKB) Operating Leases (2022 - 2026)

Cytek Biosciences (CTKB) has 5 years of Operating Leases data on file, last reported at $13.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 80.46% year-over-year to $13.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.4 million (up 80.46% YoY), and the FY2025 full-year result was $14.0 million, up 24.18% from the prior year.
• Operating Leases for Q1 2026 stood at $13.4 million, down from $14.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $17.4 million in Q2 2025 and bottomed at $7.4 million in Q1 2025.
• The 5-year median for Operating Leases is $11.5 million (2023), against an average of $12.1 million.
• The widest annual swing landed in 2023, when Operating Leases tumbled 37.81%; it then soared 80.46% in 2026.
• A 5-year view of Operating Leases shows it stood at $15.2 million in 2022, then sank by 37.81% to $9.5 million in 2023, then rose by 19.3% to $11.3 million in 2024, then grew by 24.18% to $14.0 million in 2025, then decreased by 4.28% to $13.4 million in 2026.
• The last three Operating Leases figures came in at $13.4 million (Q1 2026), $14.0 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.

Peer Comparison